[go: up one dir, main page]

FR3005420B1 - Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. - Google Patents

Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.

Info

Publication number
FR3005420B1
FR3005420B1 FR1354204A FR1354204A FR3005420B1 FR 3005420 B1 FR3005420 B1 FR 3005420B1 FR 1354204 A FR1354204 A FR 1354204A FR 1354204 A FR1354204 A FR 1354204A FR 3005420 B1 FR3005420 B1 FR 3005420B1
Authority
FR
France
Prior art keywords
suspensions
active ingredient
stabilizing
erythrocytes encapsulating
erythrocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1354204A
Other languages
English (en)
Other versions
FR3005420A1 (fr
Inventor
Yann Godfrin
Vanessa Bourgeaux
Jerome Bailly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49378358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3005420(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Priority to FR1354204A priority Critical patent/FR3005420B1/fr
Priority to JOP/2014/0156A priority patent/JO3549B1/ar
Priority to CA2910975A priority patent/CA2910975C/fr
Priority to US14/889,083 priority patent/US10286008B2/en
Priority to SG11201509062RA priority patent/SG11201509062RA/en
Priority to JP2016512361A priority patent/JP6625970B2/ja
Priority to ES14726095T priority patent/ES2729343T3/es
Priority to KR1020157034227A priority patent/KR102013731B1/ko
Priority to HK16106710.8A priority patent/HK1218714B/zh
Priority to EP14726095.4A priority patent/EP2994116B1/fr
Priority to AU2014264650A priority patent/AU2014264650B2/en
Priority to RU2015152127A priority patent/RU2668688C2/ru
Priority to CN201480025939.1A priority patent/CN105246467B/zh
Priority to PCT/EP2014/059327 priority patent/WO2014180897A1/fr
Priority to TR2019/08017T priority patent/TR201908017T4/tr
Priority to MX2015015374A priority patent/MX362839B/es
Priority to BR112015028054A priority patent/BR112015028054A2/pt
Publication of FR3005420A1 publication Critical patent/FR3005420A1/fr
Publication of FR3005420B1 publication Critical patent/FR3005420B1/fr
Application granted granted Critical
Priority to IL242468A priority patent/IL242468B/en
Priority to CL2015003273A priority patent/CL2015003273A1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1354204A 2013-05-07 2013-05-07 Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. Active FR3005420B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR1354204A FR3005420B1 (fr) 2013-05-07 2013-05-07 Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
JOP/2014/0156A JO3549B1 (ar) 2013-05-07 2014-05-05 طريقة لاستقرار مُعَلَّقَات خلايا الدم الحمراء المشتملة على مُكوّن نشط والمُعَلَّقَات التي يتم الحصول عليها
AU2014264650A AU2014264650B2 (en) 2013-05-07 2014-05-07 Method for stabilising suspensions of red blood cells encapsulating an active ingredient, the suspensions obtained
PCT/EP2014/059327 WO2014180897A1 (fr) 2013-05-07 2014-05-07 Procédé de stabilisation de suspensions de globules rouges encapsulant un principe actif et suspensions ainsi obtenues
SG11201509062RA SG11201509062RA (en) 2013-05-07 2014-05-07 Method for stabilising suspensions of red blood cells encapsulating an active ingredient, the suspensions obtained
JP2016512361A JP6625970B2 (ja) 2013-05-07 2014-05-07 活性成分を封入する赤血球の懸濁液及び得られた懸濁液を安定化させるための方法
ES14726095T ES2729343T3 (es) 2013-05-07 2014-05-07 Procedimiento para estabilizar suspensiones de glóbulos rojos que encapsulan un principio activo y las suspensiones obtenidas
KR1020157034227A KR102013731B1 (ko) 2013-05-07 2014-05-07 활성 성분을 캡슐화하는 적혈구의 현탁물을 안정화하는 방법, 수득되는 현탁물
HK16106710.8A HK1218714B (zh) 2013-05-07 2014-05-07 用於稳定包封有活性成分之红细胞的悬浮液的方法、所获得的悬浮液
EP14726095.4A EP2994116B1 (fr) 2013-05-07 2014-05-07 Procédé de stabilisation de suspensions de globules rouges encapsulant un principe actif et suspensions ainsi obtenues
CA2910975A CA2910975C (fr) 2013-05-07 2014-05-07 Procede de stabilisation de suspensions de globules rouges encapsulant un principe actif et suspensions ainsi obtenues
RU2015152127A RU2668688C2 (ru) 2013-05-07 2014-05-07 Способ стабилизации суспензий эритроцитов с инкапсулированным активным ингредиентом и их получение
CN201480025939.1A CN105246467B (zh) 2013-05-07 2014-05-07 用于稳定包封有活性成分之红细胞的悬浮液的方法、所获得的悬浮液
US14/889,083 US10286008B2 (en) 2013-05-07 2014-05-07 Method for stabilising suspensions of red blood cells encapsulating an active ingredient
TR2019/08017T TR201908017T4 (tr) 2013-05-07 2014-05-07 Bir etken maddeyi kapsülleyen kırmızı kan hücreleri süspansiyonunun stabilize edilmesi yöntemi, elde edilen süspansiyon.
MX2015015374A MX362839B (es) 2013-05-07 2014-05-07 Método para estabilizar suspensiones de glóbulos rojos que encapsulan un ingrediente activo, y suspensiones obtenidas.
BR112015028054A BR112015028054A2 (pt) 2013-05-07 2014-05-07 método para obter uma suspensão estabilizada de glóbulos vermelhos e suspensão estabilizada
IL242468A IL242468B (en) 2013-05-07 2015-11-05 A method for stabilizing suspensions of red blood cells encapsulating an active substance, the resulting suspension
CL2015003273A CL2015003273A1 (es) 2013-05-07 2015-11-06 Método para estabilizar suspensiones de glóbulos rojos que encapsulan un ingrediente activo, y suspensiones obtenidas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1354204A FR3005420B1 (fr) 2013-05-07 2013-05-07 Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.

Publications (2)

Publication Number Publication Date
FR3005420A1 FR3005420A1 (fr) 2014-11-14
FR3005420B1 true FR3005420B1 (fr) 2015-09-18

Family

ID=49378358

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1354204A Active FR3005420B1 (fr) 2013-05-07 2013-05-07 Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.

Country Status (18)

Country Link
US (1) US10286008B2 (fr)
EP (1) EP2994116B1 (fr)
JP (1) JP6625970B2 (fr)
KR (1) KR102013731B1 (fr)
CN (1) CN105246467B (fr)
AU (1) AU2014264650B2 (fr)
BR (1) BR112015028054A2 (fr)
CA (1) CA2910975C (fr)
CL (1) CL2015003273A1 (fr)
ES (1) ES2729343T3 (fr)
FR (1) FR3005420B1 (fr)
IL (1) IL242468B (fr)
JO (1) JO3549B1 (fr)
MX (1) MX362839B (fr)
RU (1) RU2668688C2 (fr)
SG (1) SG11201509062RA (fr)
TR (1) TR201908017T4 (fr)
WO (1) WO2014180897A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
WO2015153102A1 (fr) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Méthodes et compositions d'immunomodulation
EP3187190A1 (fr) 2015-12-31 2017-07-05 Erytech Pharma Procédé de traitement d'un mammifère, y compris l'être humain, contre le cancer au moyen de la méthionine et la déplétion de l'asparagine
SG10202007639SA (en) 2016-01-11 2020-09-29 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
SMT202200157T1 (it) 2016-08-08 2022-05-12 Aerase Inc Composizioni e procedimenti per trattare il cancro con deplezione di arginina e agenti immuno-oncologici
WO2019042628A1 (fr) 2017-08-31 2019-03-07 Erytech Pharma Arginine déiminase encapsulée à l'intérieur d'érythrocytes et leur utilisation dans le traitement du cancer et d'une déficience en arginase-1
EP3449935A1 (fr) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulée à l'intérieur des érythrocytes et leur utilisation dans le traitement du cancer et de la déficience en arginase-1
MX2020005933A (es) 2017-12-05 2021-01-15 Aerase Inc Metodo y composicion para tratar la deficiencia de arginasa 1.
EP3866837A1 (fr) 2018-10-19 2021-08-25 AERase, Inc. Thérapie d'épuisement d'arginine pour le traitement d'une déficience en gamt
JP7257182B2 (ja) * 2019-02-27 2023-04-13 京セラ株式会社 検査装置および検査方法
JP2022545738A (ja) 2019-08-30 2022-10-28 アエグリア バイオセラピューティクス， インク． ヒト組換えアルギナーゼ１の製造方法およびその使用
EP4147730A1 (fr) * 2021-09-09 2023-03-15 ETH Zurich Procédé de préparation de matériau d'hydrogel fonctionnel pouvant être injecté
WO2023067200A1 (fr) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulée dans des globules rouges pour le traitement du cancer du pancréas

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655801C2 (de) * 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
DE2740053A1 (de) 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
US4389209A (en) * 1980-06-18 1983-06-21 The United States Of America As Represented By The Secretary Of Agriculture Method of providing systemic protection from bloodsucking insects and other parasites using encapsulated additives in resealed erythrocytes
FR2529463B1 (fr) 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
US4801777A (en) 1987-09-03 1989-01-31 Vanderbilt University Blood rewarming method and apparatus
FR2660864A1 (fr) * 1990-04-13 1991-10-18 Guerbet Sa Composition de contraste, procede de preparation de cette composition et application a l'imagerie.
FR2678512B1 (fr) 1991-07-03 1995-06-30 Novacell Machine a internaliser.
EP0690671B1 (fr) 1993-03-23 2004-08-04 Cbr Laboratories, Inc. Methode et appareil d'encapsulation de substances biologiquement actives dans des cellules
DK0754301T3 (da) 1994-04-05 1999-06-07 North Gen Hospital Nhs Trust Fremstilling og stabilisering af cellesuspensioner
EP0882448B1 (fr) * 1997-05-05 2005-01-12 DIDECO S.r.l. Méthode d'encapsulation d'agents biologiquement actifs dans des erythrocytes et appareil
US6610702B2 (en) 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
RU2271540C2 (ru) * 2003-07-21 2006-03-10 Ставропольский научно-иследовательский противочумный институт Способ получения биомагноиммуносорбента для обнаружения бактериальных антигенов (варианты)
FR2873925B1 (fr) * 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
ES2749574T3 (es) 2005-11-01 2020-03-23 Wyeth Llc Solución de cloruro sódico para la reconstitución de fármacos
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase

Also Published As

Publication number Publication date
JP2016517899A (ja) 2016-06-20
HK1218714A1 (zh) 2017-03-10
KR102013731B1 (ko) 2019-08-23
CA2910975A1 (fr) 2014-11-13
WO2014180897A1 (fr) 2014-11-13
CN105246467B (zh) 2018-11-27
KR20160005077A (ko) 2016-01-13
IL242468B (en) 2020-03-31
BR112015028054A2 (pt) 2017-07-25
TR201908017T4 (tr) 2019-06-21
EP2994116A1 (fr) 2016-03-16
RU2015152127A3 (fr) 2018-03-30
RU2015152127A (ru) 2017-06-13
MX2015015374A (es) 2016-06-02
AU2014264650A1 (en) 2015-11-19
FR3005420A1 (fr) 2014-11-14
CA2910975C (fr) 2020-01-21
US10286008B2 (en) 2019-05-14
RU2668688C2 (ru) 2018-10-02
EP2994116B1 (fr) 2019-03-06
SG11201509062RA (en) 2015-12-30
JO3549B1 (ar) 2020-07-05
ES2729343T3 (es) 2019-10-31
JP6625970B2 (ja) 2019-12-25
CL2015003273A1 (es) 2016-05-27
CN105246467A (zh) 2016-01-13
MX362839B (es) 2019-02-19
AU2014264650B2 (en) 2018-10-18
US20160095884A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
FR3005420B1 (fr) Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
MY183004A (en) Heart rate sensor with high-aspect-ratio photodetector element
HUE049893T2 (hu) Cikloalkilpiridil-csoporttal rendelkezõ kondenzált heterociklusos vegyület vagy sója, a vegyületet tartalmazó mezõgazdasági vagy kertészeti rovarirtószer és ilyen célra való alkalmazási módszer
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
EA201500386A1 (ru) Пестицидные смеси, содержащие жасмоновую кислоту или её производное
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
LT3003268T (lt) Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
EA201401080A1 (ru) Порошок никотинамида, способ и устройство для его получения
DK3402783T3 (da) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
DK3402781T3 (da) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4,5]-decan-derivater
FR2995222B1 (fr) Procede alternatif de microencapsulation de principe actif
BR112017013156A2 (pt) combinações de composto ativo.
NZ627473A (en) Aryloxyacetamide compound and pesticide
FR3010298B1 (fr) Procede d'analyse physiologique par stabilisation d'une surtension
ITUB20161235A1 (it) Irroratrice, soprattutto per frutteti.
FR3018955B1 (fr) Procede de fabrication d'une electrode, electrode ainsi fabriquee et systeme electrochimique la comprenant.
FR3027522B1 (fr) Composition poreuse chargee en principe actif
IL240543B (en) Catalyst and method for producing optically active anti-1,2-nitroalkanol compound
PL2883461T3 (pl) Sposób wytwarzania aktywnej folistatyny
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб
FR3017029B1 (fr) Principe actif nutritionnel obtenu a partir de vaccinium angustifolium, composition le contenant et utilisation
HUE036037T2 (hu) (3S,3S')4,4'-Diszulfándiil-bisz(3-aminobután-1-szulfonsav), azaz ABSD, L-lizinnel képezett kristályos alakja
IN2013CH04635A (fr)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13